CPHI Milan: SGD Pharma Showcases Siliconized Molded Glass Vials for Sustainable Packaging
SGD Pharma will exhibit its siliconized molded glass vials at CPHI Milan as part of its sustainable offerings
SGD Pharma, a worldwide supplier of pharmaceutical glass packaging solutions, shared on Oct. 1, 2024, that it will showcase a new variety of products and services at CPHI Milan in Milan, Italy, from Oct. 8–10. The company is going to show its siliconized molded glass vials during the presentation. A company press release states that the siliconization process is an internal treatment that adds extra features to a glass vial.
The internal silicon coating offers a safeguard for delicate, potent, and thick drug products. The coating helps to minimize interaction with the packaging and maintains the integrity of the drug product, as stated in the press release. SGD mentioned in the release that siliconization is available for all types of glass and for vials ranging in size from 3 mL to 500 mL, including both clear and amber glass. The siliconization process is suitable for all routes of administration, including parenteral, oral, and nasal administration.
“SGDPharma’s €5 million [US$5.5 million] investment in the siliconization production line at its advanced Saint-Quentin Lamotte (SQLM) plant [in France] allows customers to receive orders of high-performance vials quickly, meeting global demand,” the company stated in its press release.
SGD Pharma stated in its press release that the increasing need for the approval of biologics, new therapeutic methods, and the creation of specialty drugs is leading to a demand for ready-to-use (RTU) packaging. The company provides a ready-to-use solution in molded glass, featuring its Sterinity EZ-fill vials (a registered trademark of Stevanato Group and/or its affiliates in one or more jurisdictions). The Sterinity EZ-fill vials are made to meet the tough standards of the pharmaceutical industry. These vials are better and more adaptable, which helps speed up the time it takes to bring products to market and lowers overall costs, as stated in the press release. Sterinity can be used in many areas of veterinary and human health.
“At CPHI 2024, we are showcasing solutions designed with the needs of our pharmaceutical and veterinary customers in mind, focused on helping them bring their drugs to market quickly and safely.”Our focus on innovation shows through our commitment to sustainability, a key part of our company strategy. “We are excited to continue our support for the UN Global Compact for the fifth consecutive year and are proud of the strides we’ve made in lowering carbon emissions at our global glass manufacturing sites,” stated Olivier Rousseau, CEO of SGD Pharma, in the release. “SGD Pharma is working on renewable energy projects, like upgrading our furnace at Saint Quentin Lamotte (SQLM) in France and adding solar panels at our Vemula, India, plant. These efforts highlight our commitment to reducing carbon emissions, aiming for a 35% decrease from 2020 levels by 2030, and a 65% reduction by 2040.” We are committed to our customers, partners, and the planet as we work towards a safer and healthier environment.
The company is set to showcase an addition to its Sterinity range at CPHI, featuring the introduction of aRTUTypeIImoldedglassvial. Sterinity RTU in Type II will first be available in size 10H, with more sizes expected to be introduced in 2025. Sterinity Type I is now offered in sizes of 10 mL, 20 mL, 25 mL, 50 mL, and 100 mL. Type I comes in clear and amber glass options.
SGD Pharma will also showcase an expansion of its IDENCY range, featuring 20 mL and 6 mL sizes. The company is going to add new caps for its Ensiemo syrup bottles. The presentation will cover these points:
IDENCY is a Type I glass vial that merges the advantages of molded and tubular technologies, specifically designed for sensitive parenteral drugs.
Ensiemofull offers a complete packaging solution, featuring a pharma-grade Type III glass vial and pipette. It is now available with polypropylene or polyethylene caps that provide tamper-evident and child-resistant closures.
The company now provides LabServices, an analytical testing service in molded glass for its customers and partners. Experts at SGD Pharma’s SQLM plant offer analytical testing for pharmaceutical and biopharmaceutical companies, contract manufacturing organizations, contract development and manufacturing organizations, and other glass manufacturers through this service. The company plans to introduce additional LabServices in 2025.
The showcase is set to take place at SGD Pharma’s booth, 20B11, during CPHI.
Source: SGD Pharma
